MarketMoodz
JPMorgan’s Top Stock Picks for June: Viasat Joins the List
JPMorgan updated its monthly top-ideas list for June across growth, income, value and shorts, adding Viasat as a new top idea. The move highlights a tilt toward communications infrastructure and healthcare names as markets enter June after a tech-led May rally.
Key Takeaways
- JPMorgan refreshed its monthly top ideas for June across growth, income, value and shorts and added Viasat as a new recommendation.
- Viasat was cited for a Lockheed Martin contract supporting NOAA aircraft and a 70% communications services / 30% defense revenue mix.
- Needham reiterated a Buy on Viasat and raised its price target to $90 from $58.
- May closed strong with tech-led gains—Nasdaq +8%, S&P 500 +5%, Dow +3% (per CNBC recap).
- Claims that Viasat’s 12-month +730% gain, its two-day ~16% drop after a shelf filing, and Eli Lilly’s >$1 trillion market cap could not be independently verified.
People Involved
- No specific individuals mentioned
Entities Involved
- JPMorganPublisher of the monthly top-ideas list and source of analyst recommendations
- Viasat Inc. (VSAT)New top idea; communications and defense satellite company with reported hybrid satcom platform
- Needham & CompanyBrokerage that reiterated a Buy on Viasat and raised its price target to $90
- Lockheed MartinPrime contractor reported to have a contract related to NOAA aircraft that involves Viasat’s platform
- NOAAEnd customer for the reported aircraft communications contract
- Eli Lilly and Company (LLY)Healthcare name featured for vaccines and infectious disease treatment; cited in JPMorgan’s list
- CVS Health Corporation (CVS)Retail health company mentioned in context of drug-plan coverage decisions
- Nasdaq CompositeMarket benchmark cited for May performance
- S&P 500Market benchmark cited for May performance
MarketMoodz Analysis
JPMorgan’s June list signals a strategic tilt: pick names that combine secular growth with contract-backed revenue and defensive earnings streams. Viasat’s inclusion—and its reported Lockheed Martin/NOAA work—points to a bet on communications infrastructure and government spending that can hold up if macro growth stalls. Needham’s upgraded target to $90 from $58 adds independent analyst conviction, but the recent shelf registration filing and short-term volatility cited in reports increase execution and dilution risk; investors should treat entry points cautiously and watch the filing’s details.
Healthcare names like Eli Lilly remain core to JPMorgan’s thinking because of durable demand for vaccines, infectious-disease treatments and weight-loss therapeutics that shape payer coverage and pricing power. That said, several headline figures in coverage—Lilly’s alleged >$1 trillion market cap and precise percent gains off summer lows—could not be independently verified, so position sizing should rely on up-to-date market data and earnings cadence rather than media summaries. CVS’s drug-plan coverage moves matter: payers can materially influence uptake and revenue trajectories for blockbuster therapies.
What to watch next: the details and timing of Viasat’s shelf offering and any share issuance, confirmation of contract milestones from Lockheed Martin/NOAA, quarterly guidance from Viasat and Lilly, and payer coverage decisions at CVS. Also monitor macro signals—economic data and Fed commentary—that could shift the bank’s growth vs. defensive weighting; JPMorgan’s monthly list is a directional input, not a substitute for company-level due diligence.
Source: Original Article